McKinsey & Company Skip main navigation

Pharmaceuticals & Medical Products

We work with leading innovators in pharmaceuticals and medical products to ask the right questions, provide insights, and deliver results. We help clients build capabilities to deliver lasting business impact.

Our expertise

Proprietary tools & solutions

Our sophisticated tools and solutions help pharmaceutical and medical product companies during the entire product development lifecycle, from discovery through post-launch. Many were created specifically to address the unique challenges that PMP companies confront.more

Latest thinking

Developing capabilities in supply chain, Marketing, R&D
compendium

Unlocking pharma growth : Navigating the intricacies of emerging markets

Emerging markets offer attractive opportunities for growth, but pharma companies need to navigate the intricacies of individual markets and develop tailored capabilities and commercial models to tackle the challenges.more

Healthcare challenges in China
compendium | McKinsey Greater China

Healthcare in China: Entering uncharted waters

China’s healthcare sector continues to develop at an astonishing rate, but challenges remain. McKinsey’s Healthcare Practice in China has published a new report which offers a diversity of perspectives on this substantial, complex and important domain. A selection of articles are published on the McKinsey China Healthcare page.

Operations for the executive suite
compendium

Operations for the executive suite

Highlights specific opportunities for operations to create significant value upside for pharmacos and emphasizes the role of the executive suite in enabling this value creation

Escaping the sword of Damocles
compendium

Escaping the sword of Damocles: Toward a new future for pharmaceutical R&D

Recent years have seen a collapse in the industry’s R&D productivity. Regaining trust by delivering life-changing new drugs is still an achievable goal, but it will require discipline, creativity, and luck in equal measure. Part of the 2012 R&D compendium.

Death of a sales model, or not
compendium

Death of a sales model, or not

Discusses how pharmaceutical companies will need to adjust their traditional sales models to suit the evolving healthcare landscape

Contact

Meet our people

Michael Silber

Michael Silber

Director
Vivian Hunt

Vivian Hunt

Director
Rajesh Parekh

Rajesh Parekh

Director
More profiles

Featured insights

report | Consumer & Shopper InsightsInteracting with physicians virtually

Making sense of e-detailing in Japan's pharmaceutical sector

The branded pharmaceutical industry is performing at a level of productivity that is lower than what modern technology would allow it. Now Japan is at the leading edge of what may be a better way: e-detailing.

articleA wake-up call for Big Pharma

A wake-up call for Big Pharma

December 2011—Lower profit margins suggest a need for new business models.more